Pre-seed SAFE → accelerated Series A. Six months earlier close, funded execution instead of unfunded commitment.
Executive frame
SCQ · Should HIFP raise a pre-seed round? Can Series A be pulled forward?
Governing thought
The one sentence that governs the funding-path decision.
A $1.5M pre-seed SAFE closed in Q4 2026 unlocks the pre-Series-A gates, accelerates Series A to Q1–Q2 2027, and reshapes the founder-agreement math from "unfunded commitment" to "funded execution."
Three consequences follow:
- Fatima's Gate 1 becomes an executable transition, not a leap of faith. With pre-seed funding, Fatima has a real founder-agreement with cash-backed startup salary, equity vested against a signed board, and a runway that closes the "leave Salesforce for what exactly" question.
- ASA-LTC lead + counsel + chain-BD travel all become fundable Day 1, not "closed-when Series A" line items. The Tier 1 gaps in POV v3 collapse from 12-month wait to 90-day close.
- Series A closes on evidence, not commitments. Pulled forward to Q1–Q2 2027, the Series A pitch is anchored on 1 back-test published + ASA-LTC lead credited + counsel engaged + chain 1 MSA advancing or signed + adversarial test set live — meaningfully stronger than the current "gates targeted" pitch on unfunded runway.
Current plan vs. proposed path
Net acceleration: 6 months on Series A close, 3–6 months on MVP launch.
| Milestone | Current v3 plan | Proposed with pre-seed |
|---|---|---|
| Formation | Month 0 (Q4 2026) | Month 0 (Q4 2026) |
| Fatima Gate 1 (full-time) | Q2 2027 (~6 mo post-formation) | Q4 2026–Q1 2027 (2–3 mo post-formation) |
| ASA-LTC lead hired | Q1 2027 | Month 1–2 |
| Regulatory counsel engaged | Month 1 | Month 1 |
| Chain 1 executive conversations open | Month 1 | Month 1 |
| Chain 1 MSA signed | Q2 2027 target | Q1–Q2 2027 target |
| First back-test published | Q3–Q4 2027 | Q1–Q2 2027 |
| Adversarial test set curation partner engaged | Post-Series-A | Month 2–3 |
| D2C conversion + CAC pilot | Q2 2027 | Q1 2027 |
| Series A close | Q3 2027 | Q1–Q2 2027 |
| MVP launch | Q3 2028 | Q1–Q3 2028 |
Pre-seed SAFE structure
SAFE instrument, not priced seed. Cleaner, faster to close, avoids concept-stage valuation debate.
Size + terms
- Target: $1.5M ($1M floor, $2M ceiling — do not raise beyond $2M at pre-seed valuation).
- Instrument: SAFE — 60–90 day close cycle vs. 4–6 months for priced seed; avoids concept-stage valuation debate; conversion at Series A gives investors the valuation certainty a priced seed would.
- Post-money valuation cap: $12–15M.
- Discount to Series A: 15–20%.
- Most-favored-nation clause: yes (standard).
- Pro-rata rights: yes for lead angels ≥$250K; no for smaller checks.
- No board seat. SAFE holders convert at Series A; board comes from Series A lead.
Why these terms
- $12–15M cap reflects concept-stage-with-credible-team pricing in health-AI startups in 2026. Comparables: pre-revenue health-AI concept-stage rounds have been pricing $10–20M post-money cap through 2025–26 based on team + thesis. HIFP with three credentialed prospective founders + regulated-vertical thesis + concierge-chain distribution wedge is defensibly in the upper half.
- 15–20% discount is the market rate for a genuine pre-seed SAFE converting into a Series A within 6–9 months. Above 20% signals a distressed raise; below 15% is stingy and delays the round.
- SAFE not priced seed avoids 3–4 months of round mechanics and reduces founder-agreement complexity — SAFE holders have no governance rights until conversion.
Pre-seed sources
Ranked by fit + close-speed. Warm intros first; cold outreach as backfill. Every check must be defensible to the Series A lead.
Tier 1 · Warm strategic angels (target 40–50% of round)
- Salesforce Ventures — Sindhu + Fatima + Brandon all Salesforce-adjacent. $500K–$750K check plausible; strategic value in health/longevity signal-boosting. Fastest close.
- McKinsey partner network — Fatima's alumni relationships from her Clinical CoE lead role. Warm intros to senior partners who angel-invest in health startups. $50K–$250K checks; ~5–8 partners realistically willing at concept stage.
- Health/longevity strategic angels — H&LS execs at Microsoft (Fatima's former colleagues), Allscripts (Fatima's former team), Salesforce H&LS (Fatima's former team + Sindhu's former team), Oracle Health (Fatima's current colleagues), Function Health / Superpower founders (warmable via co-marketing outreach). $50K–$150K checks.
Tier 2 · Health-tech solo GPs + micro-funds (target 30–40%)
- Solo-GP funds focused on health tech. Examples: Vive Ventures, Ancient Sails Ventures, Kittyhawk (active in early-stage health at 2026). $150K–$500K checks. Faster diligence than institutional VCs at concept stage.
- Longevity-focused angel syndicates — AngelList syndicate leads, Kernel Health, Health2047-adjacent. $200K–$500K checks. More diligence-heavy but reputationally useful.
Tier 3 · Institutional pre-seed (target 10–20% or backfill)
- Named pre-seed VCs with health thesis — BoxGroup, Slow Ventures, Susa Ventures, K5, Everywhere Ventures. $250K–$500K checks. Slower close but validates the round to Tier 1 later.
- Health/longevity-strategic Series A leads (a16z Bio + Health, ARCH, GV, Lux) — save these for the Series A conversation. Pre-seed conversations that go poorly poison the Series A well.
- Corporate strategics (concierge chains, insurers, wealth platforms) — bad fit for pre-seed instruments; wait for Series A where their pro-rata and strategic value align.
Use of pre-seed ($1.5M target)
Fully deployed by Series A close (~9 months). Every line item is a Tier 1 gap unlock or a founder-transition enabler.
| Line item | Amount | Purpose |
|---|---|---|
| Fatima transition bridge (partial-year salary) | ~$300K | Covers Fatima's salary Q1 2027 through Series A close; enables Gate 1 to close without personal cash risk |
| ASA-LTC actuarial lead (partial-year loaded cost) | ~$350K | Enables Tier 1 gap #2 to close in Month 1–2 instead of Month 6 |
| Regulatory counsel engagement + retainer | ~$150K | Manatt or Perkins Coie + specialist WA MHMDA counsel; closes Tier 1 gap #4 |
| Adversarial test set curation partner (initial contract) | ~$150K | HiddenLayer / Robust Intelligence / Anthropic red-team services; enables Gate 7 architecture to begin |
| Brandon partial-time bridge OR early full-time transition | ~$150K | Covers Brandon's opportunity cost + partial salary while managing his 90-day gate |
| Chain 1 + F500 CHRO BD travel + coordination | ~$100K | Executive-level meetings across MDVIP, One Medical Premium (via Amazon), Executive Health Group, PartnerMD + 3 F500 CHRO conversations |
| Legal (formation, founder agreements, SAFE docs) | ~$100K | Delaware C-corp formation, founder agreements, 83(b), SAFE templates |
| Operating buffer + contingency | ~$200K | Reserve for surprises; unused converts into Series A runway |
| Total | $1.5M | Fully deployed by Series A close |
Accelerated timeline
Month-by-month Q4 2026 formation → Q1–Q2 2027 Series A close.
| Month · Quarter | Milestone |
|---|---|
| Month 0 · Q4 2026 | HIFP formed. Founder agreement signed (Fatima + Brandon commitments memorialized). Pre-seed SAFE fundraising begins. Sindhu + Fatima open chain 1 executive conversations. |
| Month 1 · Q1 2027 | Pre-seed SAFE closes ($1.5M target). Fatima transitions full-time. ASA-LTC lead + regulatory counsel + adversarial test set partner all engaged. Brandon commits to founder agreement. First chain 1 executive VP+ conversations documented. |
| Month 2 · Q1 2027 | ASA-LTC + Sindhu begin back-test data access (Kaiser NorCal DUA in-flight). Regulatory-counsel scoping memo drafted. Chain 1 MSA advancing (3+ conversations with pricing on table). D2C landing-page + email-list pilot launched. Adversarial test-set v1 (100 prompts) live. |
| Month 3 · Q1 2027 | First back-test cohort analysis in progress. Chain 1 MSA advanced or signed. D2C pilot preliminary results (CVR + CAC). Adversarial test set at 250+ prompts. Product-design v3 architecture validated in prototype. |
| Month 4 · Q1 2027 | First back-test preliminary finding: ≥20% CI narrowing on LTC-onset window (Gate 3 hit). Series A conversations opened with health/longevity-strategic + AI-forward generalist leads. Pre-seed investors named in the deck as validating capital. |
| Month 5–6 · Q2 2027 | Series A pitch cycle. Health/longevity-strategic lead + AI-forward generalist competing (target dual-lane process). Adversarial test set at 400+ prompts. Chain 1 MSA signed. First back-test paper draft in review with academic co-authors. |
| Month 7–9 · Q2 2027 | Series A close targeted ($7–9M range). MVP scoping locked. Priority Series A hires begin (Founding Engineer #1 + full-stack + back-end + compliance-ops). Advice-Boundary Architecture principles post drafted. |
| Month 9–24 · Q3 2027 → Q2 2028 | MVP build (12 months per Product Design v3 sequence). Chain 1 patient-portal integration. Planning Agent + Plan-Delta + Advice-Boundary Classifier. SOC 2 Type II in-flight → certified. Freemium D2C launch. First back-test paper published. |
| Month 24 · Q2–Q3 2028 | MVP public launch. Second concierge chain live (H1 target). Variant A OEM conversations open. First B2B2E pilot signed. |
Trade-offs + risks
Adversarial view of the pre-seed + accelerated Series A path.
Additional dilution (~5–8% earlier)
The math. $1.5M SAFE at $12–15M post-money cap converts at Series A. If Series A closes at $30–40M post-money, SAFE holders convert at (say) 15% discount = effectively ~$34M post-money conversion, ~4.4% of the Series A cap table. If Series A closes at or below the SAFE cap, SAFE holders convert at the cap — a better deal for them, meaning 10–12.5% of cap table.
Why it's worth it. Pre-seed unlocks $60–100M of expected exit value earlier by enabling faster Series A + faster MVP + faster chain-1 lock. Dilution of 5–8% on a $500M–$1B exit is $25–80M of value; the exit acceleration + risk reduction from having Fatima full-time + chain 1 signed at Series A time is worth substantially more.
Two fundraising rounds vs. one
The cost. Pre-seed SAFE + Series A = ~2× the fundraising time investment. Brandon + Fatima will spend meaningful time on pre-seed pitch cycle in Q4 2026.
Mitigation. SAFE close cycles are 60–90 days, not 4–6 months. Pre-seed conversations open with warm angels (Salesforce Ventures + McKinsey network + health strategics) that don't require the full deck cycle. Realistic time cost: 15–20 hrs/week for Fatima + Brandon over 6–8 weeks. Absorbable.
Accelerated Series A closes on less proof
The concern. Original v3 targets Series A close with 2 back-tests published + chain 1 MSA signed. Accelerated timeline targets close with 1 back-test in progress + chain 1 MSA advancing (possibly signed but not guaranteed) + adversarial test set live.
Why the risk is manageable. Series A story is anchored on team + thesis + regulatory architecture + concierge distribution, not solely evidence-of-shipping. The 6-month acceleration comes at cost of "back-test in progress" narrative vs. "back-test published" — an acceptable pitch weakness that stronger investors accept in exchange for the earlier commitment.
Pre-seed sources may poison Series A relationships
The concern. Angels or micro-funds pre-seeding HIFP might be viewed by health-strategic Series A leads as "wrong signal" if the cap table looks retail-heavy or if a competitor angel is in.
Mitigation. Curate pre-seed carefully. Salesforce Ventures + McKinsey partners + health-strategic angels are cap-table-quality signal for health/longevity-strategic Series A leads. Avoid: retail angels, competitors' investors, generalist "spray-and-pray" syndicates. Rule: every pre-seed check must be defensible to the Series A lead.
Pre-seed round fails to close $1M floor
The scenario. If we cannot raise $1M+ in a 90-day cycle, the acceleration story is dead.
Failure signal. If Salesforce Ventures + top-3 McKinsey angel targets + 2 solo GPs all pass in the first 6 weeks, the round is dead.
Decision rule. At week 6, if <$500K committed and <5 warm follow-ups, close the round with what's committed (or none) and revert to base v3 plan. Base v3 plan (no pre-seed, Series A Q3 2027) survives — we're not worse off than before, just not accelerated.
Recommended sequence
Ranked by decision-latency.
This week (October 2026)
- Brandon + Fatima decision session: is the pre-seed path approved? (This memo is the artifact for that discussion.)
- If yes: pre-seed SAFE terms draft with counsel (Manatt or Cooley); target $1.5M / $12–15M post-money cap / 15–20% discount.
- Warm-intro list assembled: Salesforce Ventures + McKinsey partners (Fatima) + health/longevity strategic angels + top-3 solo GPs + top-2 pre-seed VCs.
Next 2 weeks
- Pre-seed deck v1 drafted (short-form of Investor Deck v3 — cover, problem, category, product, wedge, team, ask; ~8 slides).
- First 5–8 warm intros initiated. Target: 3+ meetings booked in weeks 3–4.
Weeks 3–8
- Pre-seed pitch cycle. Weekly rhythm: 4–6 pitches, 2–3 follow-ups, 1–2 term sheets.
- Week 6 gate: if <$500K committed, review + decide continue vs. close.
- Target: $1M+ committed by week 6; $1.5M by week 8.
Weeks 8–12 (target Q1 2027 close)
- SAFE close. Cash in bank.
- Fatima Gate 1 executes (full-time transition). ASA-LTC lead hire. Counsel engaged. Chain 1 conversations advance.
Q2–Q3 2027 (target Series A)
- Series A pitch cycle opens with health/longevity-strategic leads + AI-forward generalist leads.
- Series A close target: Q1–Q2 2027 (revised from Q3 2027).
Founder reconciliation decisions required
Before executing this path.
- Sindhu. Does she want a pre-seed SAFE at $12–15M post-money cap? Founder-equity impact is real; her sign-off is non-negotiable.
- Fatima. Is she willing to sign a founder agreement in Q4 2026 conditioned on pre-seed close by Q1 2027, and to transition full-time within 60 days of SAFE close? This is a real commitment, faster than v3's Q2 2027 target.
- Brandon. Same question — willing to sign founder agreement conditioned on pre-seed close, and to transition to full-time (or partial with defined ramp) within 60 days?
- All three. Which pre-seed sources are off-limits (competitive conflicts, personal-relationship complications)? Curate before outreach begins.
What this doesn't change
Everything else in POV v3 holds. MVP scope, product design, regulatory architecture, four pillars, four bidder pools, seven gates, confidence 0.64, Series A raise range $7–9M — all unchanged. The funding path is a mechanic that unlocks the plan; the plan itself is not affected.